AIDX vs BMGL
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AIDX shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Concerns include weak profitability or high valuation.
The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 2/9, indicating severe operational and profitability concerns. Despite a positive revenue growth of 32.20% YoY and a gross margin of 26.29%, the company suffers from catastrophic profitability metrics including a -99.84% profit margin and -194.56% ROE, which undermine sustainable growth. Valuation multiples like Price/Book of 3.96 appear high given the lack of earnings and cash flow visibility, while the stock has lost over 80% of its value in the past year. The absence of Altman Z-Score and intrinsic value estimates further reflects data insufficiency and elevated distress risk.
Compare Another Pair
Related Comparisons
AIDX vs BMGL: Head-to-Head Comparison
This page compares 20/20 Biolabs, Inc. (AIDX) and Basel Medical Group Ltd (BMGL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.